<![CDATA[The development of personalized cancer vaccines represents a promising frontier in oncology, yet traditional approaches struggle with the complexity and volume of multi-omics data. This study addresses this challenge by introducing an AI-assisted framework for the design of personalized vaccines. The primary objective was to leverage machine learning models to identify and prioritize neoantigens from integrated genomic, transcriptomic, and proteomic data of cancer patients. The methodology involved a deep learning pipeline to analyze multi-omics datasets, predicting tumor-specific mutations and their immunogenicity. This was followed by an algorithm to select the most potent neoantigen peptides for vaccine formulation, optimizing for both MHC binding affinity and T-cell activation potential. Our results demonstrate that the AI-driven approach significantly improved the speed and accuracy of neoantigen identification compared to conventional methods. The framework successfully predicted a set of high-quality vaccine candidates for individual patients, which showed strong in silico binding to patient-specific MHC molecules. We conclude that this AI-assisted methodology provides a powerful and scalable solution for personalized vaccine design, accelerating the translation of multi-omics data into clinically actionable immunotherapies.]]>
Copyrights © 2025
